Abstract
The musculoskeletal system provides vital functions such as protection of fragile tissues, support, contribution to mineral homeostasis, and locomotion. In this chapter, we cover toxicologic pathology of importance to the nonpathologist in three major tissues comprising this system: bone and joints, skeletal muscle, and teeth. This chapter reviews the anatomy, physiology, and histology of these tissues. Best practices for study design, tissue collection and handling, and special procedures and ancillary evaluations such as biomarkers and imaging modalities are addressed. Common background lesions in nonclinical species are presented and mechanisms of toxicity and response to injury are discussed. Finally, types of animal models, risk assessment considerations, and determination of adversity are examined.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Albassam MA, Wojcinski ZW, Barsoum NJ, Smith GS (1991) Spontaneous fibro-osseous proliferative lesions in the sternums and femurs of B6C3F1 mice. Vet Pathol 28:381–388
Allen MJ (2003) Biochemical markers of bone metabolism in animals: uses and limitations. Vet Clin Pathol 32(3):101–113
Allen MR, Burr DB (2014) Bone modeling and remodeling. In: Burr DB, Allen MR (eds) Basic and applied bone biology. Academic, San Diego, pp 75–90
Armstrong RB, Phelps RO (1984) Muscle fiber type composition of the rat hindlimb. Am J Anat 171:259–272
Armstrong RB, Saubert CW 4th, Seeherman HJ, Taylor CR (1982) Distribution of fiber types in locomotory muscles of dogs. Am J Anat 163:87–98
Bendele A, McComb J, Gould T, McAbee T, Sennello G, Chlipala E, Guy M (1999) Animal models of arthritis: relevance to human disease. Toxicol Pathol 27:134–142
Blankenship B, Eighmy JJ, Hoffmann G, Schroeder M, Sharma AK, Sorden SD (2016) Findings in historical control Harlan RCCHan™:WIST rats from 104-week oral gavage studies. Toxicol Pathol 44:947–961
Bonetto A, Andersson DC, Waning DL (2015) Assessment of muscle mass and strength in mice. Bonekey Reports 4:732
Bonewald LF (2006) Mechanosensation and transduction in osteocytes. Bonekey Osteovision 3:7–15
Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26:229–238
Boskey AL (2002) Connective tissues of the musculoskeletal system. In: Slatter D (ed) Textbook of small animal surgery, 3rd edn, vol 2. Saunders, Philadelphia, pp 1774–1784
Boss JH, Misselevich I (2003) Osteonecrosis of the femoral head of laboratory animals: the lessons learned from a comparative study of osteonecrosis in man and experimental animals. Vet Pathol 40:345–354
Boyce RW, Varela A, Chouinard L, Bussiere JL, Chellman GJ, Ominsky MS, Pyrah IT (2014) Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period. Bone 64:314–325
Bregman CL, Adler RR, Morton DG, Regan KS, Yano BL (2003) Recommended tissue list for histopathologic examination in repeat-dose toxicity and carcinogenicity studies: a proposal of the Society of Toxicologic Pathology (STP). Toxicol Pathol 31:252–253
Burch PM, Hall DG, Walker EG, Bracken W, Giovanelli R, Goldstein R, Higgs RE, King NMP, Lane P, Sauer J-M, Michna L, Muniappa N, Pritt ML, Vlasakova K, Watson DE, Wescott D, Zabka TS, Glaab WE (2015) Evaluation of the relative performance of drug-induced skeletal muscle injury biomarkers in rats. Toxicol Sci 150:247–256
Burkhardt JE, Hill MA, Carlton WW, Kesterson JW (1990) Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol Online 27:162–170
Burkhardt JE, Hill MA, Turek JJ, Carlton WW (1992) Ultrastructural changes in articular cartilage of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol Online 29:230–238
Burr DB, Akkus O (2014) Bone morphology and organization. In: Burr DB, Allen MR (eds) Basic and applied bone biology. Academic, San Diego, pp 3–25
Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328
Caplazi P, Baca M, Barck K, Carano RA, DeVoss J, Lee WP, Bolon B, Diehl L (2015) Mouse models of rheumatoid arthritis. Vet Pathol 52:819–826
Castillo AB, Tarantal AF, Watnik MR, Martin RB (2002) Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta). J Orthop Res 20:1185–1189
Chamanza R, Marxfeld HA, Blanco AI, Naylor SW, Bradley AE (2010) Incidences and range of spontaneous findings in control cynomolgus monkeys (Macaca fascicularis) used in toxicity studies. Toxicol Pathol 38:642–657
Chang SC, Inui K, Lee WC, Hsuan SL, Chien MS, Chen CH, Chang SJ, Liao JW (2008) Spontaneous rhabdomyosarcoma in a young Sprague-Dawley rat. Toxicol Pathol 36:866–870
Chouinard L, Felx M, Mellal N, Varela A, Mann P, Jolette J, Samadfam R, Smith SY, Locher K, Buntich S, Ominsky MS, Pyrah I, Boyce RW (2016) Carcinogenicity risk assessment of romosozumab: a review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. Regul Toxicol Pharmacol 81:212–222
Cook JL, Kuroki K, Visco D et al (2010) The OARSI histopathology initiative: recommendations for histological assessments of osteoarthritis in the dog. Osteoarthr Cartil 18(suppl 3):S66–S79
Costa AG, Bilezikian JP (2012) Sclerostin: therapeutic horizons based upon its actions. Curr Osteoporos Rep 10:64–72
Courtney CL, Kim SN, Walsh KM, Watkins JR, Dominick MA (1991) Proliferative bone lesions in rats given anticancer compounds. Toxicol Pathol 19:184–188
Craig L, Julian M, Ferracone J (2002) The diagnosis and prognosis of synovial tumors in 16 dogs: 35 cases. Vet Pathol 39:66–73
Cui GL, Syversen U, Zhao CM, Chen D, Waldum HL (2001) Long-term omeprazole treatment suppresses body weight gain and bone mineralization in young male rats. Scand J Gastroenterol 36:1011–1015
Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL (1990) Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 322:1098–1105
De Souza AT, Cornwell PD, Dai X, Caguyong MJ, Ulrich RG (2006) Agonists of the peroxisome proliferator-activated receptor alpha induce a fiber-type-selective transcriptional response in rat skeletal muscle. Toxicol Sci 92:578–586
Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R (1993) Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690–709
Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H et al (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry nomenclature committee. J Bone Miner Res 28:2–17
Egermann M, Goldhahn J, Schneider E (2005) Animal models for fracture treatment in osteoporosis. Osteoporos Int 16:S129–S138
EMEA (European Medicines Agency CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. European Medicines Agency, London, UK. Accessed September 16, 2018
Erben RG, Jolette J, Chouinard L, Boyce R (2017) Application of histopathology and bone histomorphometry for understanding test article-related bone changes and assessing potential bone liabilities. In: Smith SY, Varela A, Samadfam R (eds) Bone toxicology, Molecular and Integrative Toxicology series. Springer, Gewerbestrasse, Switzerland, pp 253–280.
Eriksen EF (2010) Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 11:219–227
Erlandson MC, Lorbergs AL, Mathur S, Cheung AM (2016) Muscle analysis using pQCT, DXA and MRI. Eur J Radiol 85:1505–1511
Erlandson MC, Wong AKO, Szabo E, Vilayphiou N, Zulliger MA, Adachi JD, Cheung AM (2017) Muscle and myotendinous tissue properties at the distal tibia as assessed by high-resolution peripheral quantitative computed tomography. J Clin Densitom 20:226–232
Eyre DR, Weis MA, Wu JJ (2006) Articular cartilage collagen: an irreplaceable framework? Eur Cell Mater 12:57–63
FDA (2016) Osteoporosis: nonclinical evaluation of drugs intended for treatment – guidance for industry (Draft guidance). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM506366.pdf. Accessed 16 Sept 2018
Fossey S, Vahle J, Long P, Schelling S, Ernst H, Boyce RW, Jolette J, Bolon B, Bendele A, Rinke M, Healy L, High W, Roth DR, Boyle M, Leininger J (2016) Nonproliferative and proliferative lesions of the rat and mouse skeletal tissues (bones, joints, and teeth). J Toxicol Pathol 29(3 Suppl):49S–103S
Frazier KS (2017) Drug-induced physeal abnormalities in preclinical toxicity studies. Toxicol Pathol 45:869–875
Fukuda S, Cho F, Honjo S (1978) Bone growth and development of secondary ossification centers of extremities in the cynomolgus monkey (Macaca fascicularis). Exp Anim 27:387–397
Gahunia HK, Pritzker KP (2012) Effect of exercise on articular cartilage. Orthop Clin North Am 43:187–199
Gasser JA, Kneissel M (2017) Bone physiology and biology. In: Smith SY, Varela A, Samadfam R (eds) Bone toxicology, Molecular and Integrative Toxicology series. Springer, Gewerbestrasse, Switzerland, pp 27–94
Gerwin N, Bendele AM, Glasson S et al (2010) The OARSI histopathology initiative: recommendations for histological assessments of osteoarthritis in the rat. Osteoarthr Cartil 18(suppl 3):S24–S34
Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751–764
Goldring MB, Marcu KB (2009) Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther 11:224
Gopinath C, Mowat V (2014) Atlas of toxicological pathology. Springer, New York
Greaves P (2012) Musculoskeletal system. In: Greaves P (ed) Histopathology of preclinical toxicity studies, interpretation and relevance in drug safety evaluation, 4th edn. Academic, Amsterdam
Greaves P, Chouinard L, Ernst H, Mecklenburg L, Pruimboom-Brees IM, Rinke M, Rittinghausen S, Thibault S, von Erichsen J, Yoshida T (2013) Proliferative and non-proliferative lesions of the rat and mouse soft tissue, skeletal muscle and mesothelium. J Toxicol Pathol 26(3 Suppl):1S–26S
Gropp KE (2017) Effects on cancellous bone in the metaphysis. Toxiol Pathol 45:876–878
Gunson D, Gropp KE, Varela A (2013) Bone and joints. In: Haschek WM, Rousseaux CG, Wallig MA (eds) Haschek and Rousseaux’s Handbook of Toxicologic Pathology, 3rd edn. Elsevier Inc/Academic, London, pp 2761–2858
Hall AP, Westwood FR, Wadsworth PF (2006) Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. Toxicol Pathol 34:131–147
Hartke J (1996) Have you seen this? Bone anti-resorptive properties of bisphosphonates. Toxicol Pathol 24:799–800
Hartmann K, Koenen M, Schauer S, Wittig-Blaich S, Ahmad M, Baschant U, Tuckermann JP (2016) Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy. Physiol Rev 96:409–447
Hrvacic B, Situm K, Duric K, Bosnjak B, Ferencic Z, Brajsa K, Markovic S, Glojnaric I (2014) Relative potencies of three glucocorticoids to induce hypoplasia of the physis and concomitant biochemical alterations in the rat. Drug Chem Toxicol 38:272–277
Hui AY, McCarty WJ, Masuda K et al (2012) A systems biology approach to synovial joint lubrication in health, injury, and disease. Wiley Interdiscip Rev Syst Biol Med 4:15–37
Huiskes R (2000) If bone is the answer, then what is the question? J Anat 197:145–156
Institute of Medicine (1997) Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. The National Academies Press, Washington, D.C.
Jee WSS, Yao W (2001) Overview: animal models of osteopenia and osteoporosis. J Musculoskelet Neuronal Interact 1:193–207
Jerome CP, Peterson PE (2001) Nonhuman primate models in skeletal research. Bone 29:1–6
JMHW (1999) Guideline concerning the clinical evaluation method for anti-osteoporosis agents, pharmaceutical examination No. 742. In Management BoH, ed.: issued by the Prefectural Bureau Chief, Bureau of Health Management, Section of Examination and Control, Bureau of Drug Safety, Japanese Ministry of Health and Welfare
Jolette J, Wilker CE, Smith SY, Doyle N, Hardisty JF, Metcalfe AJ, Marriott TB, Fox J, Wells DS (2006) Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 34:929–940
Jones L, Allen M (2011) Animal models of osteonecrosis. Clin Rev Bone Miner Metabol 9:63–80
Kerlin R, Bolon B, Burkhardt J, Francke S, Greaves P, Meador V, Popp, J (2016) Scientific and regulatory policy committee: recommended (“best”) practices for determining, communicating, and using adverse effect data from nonclinical studies. Toxicol Pathol 44(2):147–162
Khalatbari H, Parisi MT, Kwatra N, Harrison DJ, Shulkin BL (2019) Pediatric musculoskeletal imaging: the indications for and applications of PET/computed tomography. PET Clin 14:145–174
Kiebzak GM, Smith R, Gundberg CC, Howe JC, Sacktor B (1988a) Bone status of senescent male rats: chemical, morphometric, and mechanical analysis. J Bone Miner Res 3:37–45
Kiebzak GM, Smith R, Howe JC, Gundberg CM, Sacktor B (1988b) Bone status of senescent female rats: chemical, morphometric, and biomechanical analyses. J Bone Miner Res 3:439–446
Kramer K, Kinter LB (2003) Evaluation and applications of radiotelemetry in small laboratory animals. Physiol Genomics 13:197–205
Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116:1202–1209
Kumar S, Hoffman SJ, Samadfam R, Mansell P, Jolette J, Smith SY, Guldberg RE, Fitzpatrick LA (2013) The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate. J Bone Miner Res 28:1653–1665
Lambert RGW, Østergaard M, Jaremko JL (2018) Magnetic resonance imaging in rheumatology. Magn Reson Imaging Clin N Am 26:599–613
Lamperth L, Dalakas MC, Dagani F, Anderson J, Ferrari R (1991) Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model. Lab Invest 65:742–751
Laverty S, Girard CA, Williams JM et al (2010) The OARSI histopathology initiative: recommendations for histological assessments of osteoarthritis in the rabbit. Osteoarthr Cartil 18(suppl 3):S53–S65
Leininger JR, Schutten M (2017) Oral cavity, teeth, and gingiva. In: Suttie AW, Leininger JR, Bradley AE (eds) Boorman’s pathology of the rat reference and atlas, 2nd edn. Elsevier, London
Lelovas PP, Xanthos TT, Thoma SE, Lyritis GP, Dontas IA (2008) The laboratory rat as an animal model for osteoporosis research. Comp Med 58:424–430
Lin ASP, Boyd G, Varela A, Guldberg RE (2017) Biomechanics. In: Smith SY, Varela A, Samadfam R (eds) Bone toxicology, Molecular and Integrative Toxicology series. Springer, Gewerbestrasse, Switzerland, pp 229–252
Little CB, Zaki S (2012) What constitutes an “animal model of osteoarthritis”: the need for consensus? Osteoarthr Cartil 20:261–267
Loberg LI, Logan M, Barnhart K, Fossey S, Whitney K (2017) Bone marrow findings secondary to antineoplastic compounds: hematopoietic, bone, and cytokine cross talk. Toxicol Pathol 45:879–883
Lui JC, Baron J (2011) Effects of glucocorticoids on the growth plate. Endocr Dev 20:187–193
Mahler JE, Flagler ND, Malarkey DE, Mann PC, Haseman JK, Eastin W (1998) Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice. Toxicol Pathol 26:501–511
Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884
McCoy AM (2015) Animal models of osteoarthritis: comparisons and key considerations. Vet Pathol 52:803–818
McLaughlin F, Mackintosh J, Hayes BP, McLaren A, Uings IJ, Salmon P, Humphreys J, Meldrum E, Farrow SN (2002) Glucocorticoid-induced osteopenia in the mouse as assessed by histomorphometry, microcomputed tomography, and biochemical markers. Bone 30:924–930
Melli G, Chaudhry V, Cornblath DR (2005) Rhabdomyolysis - an evaluation of 475 hospitalized patients. Medicine 84:377–385
Nathwani RA, Pais S, Reynolds TB, Kaplowitz N (2005) Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 41:380–382
National Toxicology Program (1990) Toxicology and carcinogenesis studies of sodium fluoride (CAS No. 781-49-4) in F344/N rats and B6C3F1 mice (drinking water studies). Natl. Toxicol Program Tech Rep Ser 393:1–448
Nyska A, Maronpot RR, Long PH, Roycroft JH, Hailey JR, Travlos GS, Ghanayem BI (1999) Disseminated thrombosis and bone infarction in female rats following inhalation exposure to 2-butoxyethanol. Toxicol Pathol 27:287–294
Palazzi X, Burkhardt JE, Caplain H, Dellarco V, Fant P, Foster JR, Francke S, Germann P, Groters S, Harada T, Harleman J, Inui K, Kaufmann W, Lenz B, Nagai H, Pohlmeyer-Esch G, Schulte A, Skydsgaard M, Tomlinson L, Wood CE, Yoshida M (2016) Characterizing “adversity” of pathology findings in nonclinical toxicity studies: results from the 4th ESTP international expert workshop. Toxicol Pathol 44:810–824
Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM et al (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595–610
Pelletier JP, Troncy E, Bertaim T, Thibaud D, Goulet AC, Abram F, Caron J, Boileau C, d'Anjou MA, Moreau M, Lussier B, Martel-Pelletier J (2011) Treatment with tiludronic acid helps reduce the development of experimental osteoarthritis lesions in dogs with anterior cruciate ligament transection followed by reconstructive surgery: a 1-year study with quantitative magnetic resonance imaging. J Rheumatol 38:118–128
Pratesi A, Tarantini F, Di Bari M (2013) Skeletal muscle: an endocrine organ. Clin Cases Miner Bone Metab 10:11–14
Pritt ML, Hall DG, Recknor J, Credille KM, Brown DD, Yumibe NP, Schultze AE, Watson DE (2008) Fabp3 as a biomarker of skeletal muscle toxicity in the rat: comparison with conventional biomarkers. Toxicol Sci 103:382–396
Prysor-Jones RA, Jenkins JS (1980) Effect of excessive secretion of growth hormone on tissues of the rat, with particular reference to the heart and skeletal muscle. J Endocrinol 85:75–82
Renberg WC (2005) Pathophysiology and management of arthritis. Vet Clin North Am Small Anim Pract 35:1073–1091
Sato J, Doi T, Kanno T, Wako Y, Tsuchitani M, Narama I (2012a) Histopathology of incidental findings in cynomolgus monkeys (Macaca Fascicularis) used in toxicity studies. J Toxicol Pathol 25:63–101
Sato J, Doi T, Wako Y, Hamamura M, Kanno T, Tsuchitani M, Narama I (2012b) Histopathology of incidental findings in beagles used in toxicity studies. J Toxicol Pathol 25:103–134
Schiaffino S, Reggiani C (2011) Fiber types in mammalian skeletal muscles. Physiol Rev 91:1447–1531
Scott JE, Stockwell RA (2006) Cartilage elasticity resides in shape module decoran and aggrecan sumps of damping fluid: implications in osteoarthrosis. J Physiol 574:643–650
Shea JE, Miller SC (2005) Skeletal function and structure: implication for tissue-targeted therapeutics. Adv Drug Deliv Rev 57:945–957
Shelton GD, Engvall E (2005) Canine and feline models of human inherited muscle diseases. Neuromuscul Disord 15:127–138
Siebel M, Robins SP, Bilezikian JP (2006) Dynamics of bone and cartilage metabolism, 2nd edn. Elsevier, Burlington
Smith SY, Samadfam R (2017) Biochemical markers of bone turnover. In: Smith SY, Varela A, Samadfam R (eds) Bone toxicology, Molecular and Integrative Toxicology series. Springer, Gewerbestrasse, Switzerland, pp 175–202
Smith S, Varela A, Jolette J (2011) Nonhuman primate models of osteoporosis. In: Duque G and Watanabe K (eds) Osteoporosis research, Animal models series. Springer, London, pp 135–157
Smith SY, Doyle N, Felx M (2017) Introduction and considerations in bone toxicology. In: Smith SY, Varela A, Samadfam R (eds) Bone toxicology, Molecular and Integrative Toxicology series. Springer, Gewerbestrasse, Switzerland, pp 3–26.
Thompson RC (1973) Heparin osteoporosis: an experimental model using rats. J Bone Joint Surg 55:606–612
Vahle JL (2017) Role of anatomic pathology in skeletal evaluations: applying INHAND diagnostic criteria. Toxicol Pathol 45:845–850
Vahle JL, Sato M, Long GG, Yound JK, Francis PC, Engelhardt JA, Westmore MS, Ma YL, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance for human safety. Toxicol Pathol 30:312–321
Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M (2004) Bone neoplasms in F344 rats give teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426–438
Vahle JL, Zuehlke U, Schmidt A, Westmore M, Chen P, Sato M (2008) Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res 23:2033–2039
Vahle JL, Leininger JR, Long PH, Hall DG, Ernst H (2013) Bone, muscle, and tooth. In: Sahota PS, Popp JA, Hardisty JF, Gopinath C (eds) Toxicologic pathology: nonclinical safety assessment. CRC Press, Boca Raton
Vahle JL, Ma YL, Burr D (2015) Skeletal assessments in the nonhuman primate. In: Bluemel J, Korte S, Schenck E, Weinbauer G (eds) The nonhuman primate in nonclinical drug development and safety assessment. Elsevier/Academic Press, Amsterdam, pp 606–627
Varela A (2017) Skeletal Imaging. In: Smith SY, Varela A, Samadfam R (eds) Bone toxicology, Molecular and Integrative Toxicology series. Springer, Gewerbestrasse, Switzerland/New York, pp 203–228
Varela A, Jolette J (2018) Bone toolbox: biomarkers, imaging tools, biomechanics and histomorphometry. Toxicol Pathol 46:511–529
Vassallo JD, Janovitz EB, Wescott DM, Chadwick C, Lowe-Krentz LJ, Lehman-McKeeman LD (2009) Biomarkers of drug-induced skeletal muscle injury in the rat: troponin I and myoglobin. Toxicol Sci 111:402–412
Vaughan J (1981a) Bone as a tissue. In: The physiology of bone, 3rd edn. Oxford University Press, London, pp 1–26
Vaughan J (1981b) Cellular elements of the skeleton. In: The physiology of bone, 3rd edn. Oxford University Press, London, pp 27–55
Vonderfecht SL, Stone ML, Eversole RR, Yancey MF, Schuette MR, Duncan BA, Ware JA (2004) Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence. Toxicol Pathol 32:318–325
Wancket LM (2017) Bone and joint medical devices: methods, models, and regulations. Toxicol Pathol 45:925–930
Wang F, Wang J, He J, Li W, Li J, Chen S, Zhang P, Liu H, Chen X (2017) Serum miRNAs miR-23a, 206, and 499 as potential biomarkers for skeletal muscle atrophy. Biomed Res Int 2017:8361237
Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC (2005) Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol 33:246–257
Westwood FR, Scott RC, Marsden AM, Bigley A, Randall K (2008) Rosuvastatin: characterization of induced myopathy in the rat. Toxicol Pathol 36:345–352
Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, Hill JJ, Jalenak M, Kelley P, Knight A, Maylor R, OHara D, Pearson A, Quazi A, Ryerson S, Tan XY, Tomkinson KN, Veldman GM, Widom A, Wright JF, Wudyka S, Zhao L, Wolfman NM (2003) Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300:965–971
Willmann R, Possekel S, Dubach-Powell J, Meier T, Ruegg MA (2009) Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord 19:241–249
Yanagihara GR, de Paiva AG, Neto MP, Torres LH, Shimano AC, Louzada MJQ, Annoni R, de Oliveira Penoni AC (2015) Effects of long-term administration of omeprazole on bone mineral density and the mechanical properties of the bone. Rev Bras Ortop 50:232–238
Yang Y (2013) Skeletal morphogenesis and embryonic development. In: Rosen CJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 8th edn. Wiley, Ames, Iowa, pp 3–14
Yarovaya N, Kramarova L, Borg J, Kovalenko S, Caragounis A, Linnane A (2002) Age-related atrophy of rat soleus muscle is accompanied by changes in fibre type composition, bioenergy decline and mtDNA rearrangements. Biogerontology 3:25–27
Zoetis T, Tassinari MS, Bagi C, Walthall K, Hurtt ME (2003) Species comparison of postnatal bone growth and development. Birth Defects Res B Dev Reprod Toxicol 68:86–110
Zwicker GM, Eyster RC (1996) Proliferative bone lesions in rats fed a diet containing glucocorticoid for up to two years. Toxicol Pathol 24:246–250
Acknowledgments
The authors thank Dr. John Vahle for his review of the bone and joint section of this chapter and David Sabio for preparation of Fig. 1.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this chapter
Cite this chapter
Fossey, S.L., Hall, D.G., Suttie, A.W., Guillot, M., Varela, A. (2019). Pathology of Bone, Skeletal Muscle, and Tooth. In: Steinbach, T., Patrick, D., Cosenza, M. (eds) Toxicologic Pathology for Non-Pathologists. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9777-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9777-0_14
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9776-3
Online ISBN: 978-1-4939-9777-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)